NCT05971251View on ClinicalTrials.gov

Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Loncastuximab Tesirine and Acalabrutinib

Will be given on Day 1 of each cycle with each cycle being 21 days, and is being added to BID Acalabrutinib

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

Sponsors

Collaborators (1)

ADC Therapeutics S.A.
All Listed Sponsors
collaborator

ADC Therapeutics S.A.

INDUSTRY

lead

University of Alabama at Birmingham

OTHER